EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV

Vikas S Sridhar iD, Francesco Cosentino, Samuel Dagogo-Jack, Darren K McGuire, Richard E Pratley, Nilo B Cater, Margaret Noyes Essex, James P Mancuso, Yujie Zhao, David Z I Cherney iD

Diabetes, Obesity and Metabolism · 2024-11 · 26 (11) · 5336-5346

DOI: 10.1111/dom.15895 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 02.09.2024. Verfasst von Vikas S Sridhar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Uric Acid, Bridged Bicyclo Compounds, Heterocyclic, Gout. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in collaboration with Pfizer Inc., New York, NY, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To conduct post hoc analyses of the VERTIS CV (NCT01986881) trial to explore the effects of ertugliflozin on serum uric acid (UA) and gout‐related outcomes. Materials and Methods Participants with type 2 diabetes and atherosclerotic cardiovascular disease were randomised (1:1:1) to placebo, ertugliflozin 5 mg or ertugliflozin 15 mg. Mean UA over time (260 weeks) was evaluated for pooled ertugliflozin versus placebo overall, and by baseline quintile of UA (≤4.3 mg/dL [≤255.8 µmol/L], >4.3–5.1 mg/dL [>255.8–303.4 µmol/L], >5.1–5.8 mg/dL [>303.4–345.0 µmol/L], >5.8–6.9 mg/dL [>345.0–410.4 µmol/L] and >6.9 mg/dL [>410.4 µmol/L]), glycated haemoglobin level, albuminuria status, estimated glomerular filtration rate and KDIGO (Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease) risk category. The effect of ertugliflozin on a composite of gout onset or initiation of anti‐gout medication was assessed.

Results

The mean UA levels at baseline were 5.67 and 5.62 mg/dL in the placebo and ertugliflozin groups, respectively. Ertugliflozin reduced UA over Weeks 6–260 compared with placebo, with least squares mean (LSM) changes (95% confidence interval [CI]) from baseline at Week 260 of 0.07 mg/dL (−0.02, 0.15) and −0.19 mg/dL (−0.25, −0.13) in the placebo and pooled ertugliflozin groups, respectively. At Week 260, placebo‐adjusted LSM change (95% CI) from baseline in UA was −0.26 mg/dL (−0.36, −0.16) with ertugliflozin. Ertugliflozin was associated with reductions in UA across baseline UA quintiles compared with placebo. The incidence of the composite of gout‐related outcomes was 84/2539 (3.3%) for placebo and 133/5091 (2.6%) for ertugliflozin (hazard ratio for the composite 0.76 [95% CI 0.580, 1.002]).

Conclusions

Ertugliflozin was generally associated with lowering UA overall and across subgroups compared with placebo, and numerically reduced rates of gout‐related outcome events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Uric AcidBridged Bicyclo Compounds, HeterocyclicGoutSodium-Glucose Transporter 2 InhibitorsHumansMaleFemaleMiddle AgedAgedDouble-Blind MethodTreatment OutcomeCardiovascular Diseases

Stichwörter der Autor:innen

SGLT2 inhibitorclinical trialdiabetic nephropathyinflammationphase III trialtype 2 diabetes mellitus

Substanzen

ertugliflozinUric AcidBridged Bicyclo Compounds, HeterocyclicSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Unit of Cardiology, Karolinska Institute & Karolinska University Hospital, Stockholm, Sweden.
  • University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Division of Cardiology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
  • Parkland Health, Dallas, Texas, USA.
  • AdventHealth Translational Research Institute, Orlando, Florida, USA.

ORCID-Profile: Vikas S Sridhar, David Z I Cherney

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, in collaboration with Pfizer Inc., New York, NY, USA

Zitieren

APA

Sridhar, V. S., Cosentino, F., Dagogo-Jack, S., McGuire, D. K., Pratley, R. E., Cater, N. B., Noyes Essex, M., Mancuso, J. P., Zhao, Y., & Cherney, D. Z. I. (2024). Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV. Diabetes, Obesity and Metabolism, 26(11), 5336-5346. https://doi.org/10.1111/dom.15895

Vancouver

Sridhar VS, Cosentino F, Dagogo-Jack S, McGuire DK, Pratley RE, Cater NB, et al. Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV. Diabetes, Obesity and Metabolism. 2024;26(11):5336-5346. doi:10.1111/dom.15895

BibTeX
@article{Sridhar2024,
  author = {Sridhar, Vikas S and Cosentino, Francesco and Dagogo-Jack, Samuel and McGuire, Darren K and Pratley, Richard E and Cater, Nilo B and Noyes Essex, Margaret and Mancuso, James P and Zhao, Yujie and Cherney, David Z I},
  title = {Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  volume = {26},
  number = {11},
  pages = {5336--5346},
  doi = {10.1111/dom.15895}
}
Kostenlos starten →